ICU Medical (NSDQ:ICUI) this week posted third-quarter results that beat the overall consensus on Wall Street.
The San Clemente, California-based infusion therapy company reported profits of $31 million, or $1.43 per share, on sales of $336 million for the three months ended September 30, for a bottom-line gain of 24.4% on sales growth of 5.49% compared with Q3 2020.
Adjusted to exclude one-time items, earnings per share were $2.07, 27¢ ahead of The Street, where analysts were looking for sales of $314.3 million.
“Third-quarter results were generally in line with our expectations,” CEO Vivek Jain said in a news release.
ICU Medical did not provide a financial outlook for the remainder of the year.
Shares in ICUI were up 2.10% to $245.69 apiece at market open.